Navigation Links
Intrexon and Rentokil Enter into Research and Development Agreement to Explore a New Generation of Highly-Effective, Sustainable Pest Controls
Date:9/13/2013

GERMANTOWN, Md., Sept. 13, 2013 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, announced today that it has agreed to a joint research and development initiative with Rentokil Initial PLC that may lead to a new generation of highly-effective and sustainable pest control product and solution.

Under the agreement, Intrexon will apply its biology and science expertise to assist Rentokil in the development of specific pest control products.  The companies will also consider exploring additional areas of commercial product research and development.  Additional terms of the agreement were not disclosed.

Intrexon's Chief Operating Officer, Krish Krishnan, said Rentokil's long history of developing innovative pest control products is invaluable to the collaboration.

"Intrexon and Rentokil share a common DNA: an unwavering commitment to producing ground-breaking solutions," Krishnan said. "The same biotechnologies that have served and benefitted our collaborations in Health and Food will be equally valuable towards advancing our goals in Intrexon's emerging Environment group."

About Intrexon Corporation
Intrexon Corporation (NYSE: XON) is a biotechnology company focused on collaborating with companies in Health, Food, Energy, and the Environment to create biologically based products that improve the quality of life and health of the planet.  Through the company's proprietary UltraVector® platform, Intrexon provides its partners with commercial-scale design and development of complex biological systems.  The UltraVector® platform enables unprecedented control over the quality, function, and performance of living cells for a wide variety of applications.  Intrexon calls it Better DNA™ and invites you to discover more at www.dna.com.

Trademarks
Intrexon, UltraVector and Better DNA are trademarks of Intrexon and/or its affiliates.  Other names may be trademarks of their respective owners.

Safe Harbor Statement
Some of the statements made in this press release are forward-looking statements.  These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business.  Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

For more information contact:


Intrexon Corporation Contact:


Marie L. Rossi, Ph.D.

Manager, Technical Communications

Tel: +1 301-556-9944

mrossi@intrexon.com



 


'/>"/>
SOURCE Intrexon Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Synthetic Biologics and Intrexon Corporation Enter Worldwide Exclusive Collaboration for Infectious Diseases
2. Synthetic Biologics Reiterates that the Infectious Disease Collaboration with Intrexon Remains in Effect
3. Intrexon Corporation Raises $150 Million for Synthetic Biology Initiatives
4. Intrexon Organizes Around New Synthetic Biology Markets
5. Intrexon Announces Filing of Registration Statement For Proposed Initial Public Offering
6. Intrexon Prices Initial Public Offering
7. Intrexon Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option by Underwriters
8. DermTechs Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study
9. Pittsburgh Based ParentPlus Enters Collaboration with Vitrolife
10. Two Top Biological Imaging Centers Offer Powerful Free Online Tool to Researchers, Educators, and Public
11. OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... , Jan. 24, 2017  Asterias Biotherapeutics, Inc. ... field of regenerative medicine, today announced positive efficacy ... clinical trial that showed additional motor function improvement ... million AST-OPC1 cells in AIS-A patients with complete ... of upper extremity motor function is critically important ...
(Date:1/24/2017)... ... January 24, 2017 , ... Men ... serum leptin levels had a positive association with increased prostate growth or benign ... the International Neurourology Journal involved 571 Korean men who underwent urological examinations, ...
(Date:1/24/2017)... ... 24, 2017 , ... Nor-Tech’s leading-edge demo cluster is proving ... Intel KNL. , Currently Cal Tech researchers are testing their code on ... cluster is a no-cost, no-strings opportunity for current and prospective clients to test-drive ...
(Date:1/24/2017)... ... January 23, 2017 , ... Edward ... first-ever recipient of the National Academy of Sciences Prize in Food and Agriculture ... nutrition. , The annual National Academy of Sciences (NAS) Prize in Food and ...
Breaking Biology Technology:
(Date:1/19/2017)... , January 19, 2017 According to a new ... and Forecast, 2014 - 2022," the global biometric sensor market is expected to ... to 2022. In 2015, Asia-Pacific dominated the global market ... private sectors. Continue Reading ... ...
(Date:1/18/2017)... -- In vitro diagnostic (IVD) companies were very active in ... Kalorama Information expects that trend to continue – though ... uncertainty in reimbursement and healthcare reform in ... acquisitions landscape. Instead of looking to buy technology, the ... of their home country and also to increase their ...
(Date:1/13/2017)... N.Y. , Jan. 13, 2017 ... technology solutions for the homecare industry, including Electronic ... homecare industry expert, Justin Jugs, as Senior Vice ... more than 15 years of homecare experience to ... in developing strategic plans to align Sandata,s suite ...
Breaking Biology News(10 mins):